Search Results

The Foundation for the National Institutes of Health will award the 2024 Charles A. Sanders, MD, Partnership Award to the National Institutes of Health’s National Institute of Neurological Disorders and Stroke, AbbVie, and Robert and Sarah Newcomb.

The Foundation for the National Institutes of Health announces that Love Collins, III, has joined as Vice President of Advancement.

Kyverna Therapeutics, Inc. announced the publication in Nature Reviews Immunology of a manuscript co-authored with the National Institutes of Health titled “Chimeric antigen receptor T cell therapy for autoimmune disease”.

The Foundation for the National Institutes of Health announces two additions to the FNIH Board of Directors: James W. Down, former Vice Chairman of Mercer Management Consulting, and Perry Steiner, Chairman and CEO of Xactus.

The Foundation for the National Institutes of Health announces the launch of a public-private partnership to build the largest data source for amyotrophic lateral sclerosis and expedite the identification of biomarkers and clinical outcome assessments that would allow earlier diagnosis and accelerated drug development for people living with the disease.

Pluri Inc., a leading biotechnology company that transforms cells into solutions, announced the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has exercised its option for year two of the three-year $4.2 million contract it entered into with Pluri in July 2023.

Clinical Laserthermia Systems Americas, Inc. announced it has received its second order from the National Institutes of Health Clinical Center for its TRANBERG™ Thermal Therapy System accessories.

Xylyx Bio, Inc. announced that it has been awarded a Small Business Innovation Research Fast-Track grant from the National Cancer Institute of the National Institutes of Health to advance commercial development of its InMatrico® disease modeling and drug testing platform to help scientists discover and test drug candidates for metastatic breast cancer.

BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company utilizing a powerful TCR discovery platform to identify novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced a strategic collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health.

The Foundation for the National Institutes of Health announces two new additions to the FNIH Board of Directors, Nina Kjellson, General Partner at Canaan, and Charles Reinhart III, Chief Financial Officer at Pacira BioSciences, Inc.